Pre market trades, page-5

http://www.businesswire.com/news/ho...mended-Orphan-Designation-Europe#.VUAZHSGqpBc

April 27, 2015 11:22 PM Eastern Daylight Time
MELBOURNE, Australia--(BUSINESS WIRE)--Prana Biotechnology (ASXBT) (NASDAQRAN) is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC).

“We welcome the positive opinion from COMP for PBT2 to receive orphan designation to treat Huntington disease in Europe,” said Prana Chairman and CEO Geoffrey Kempler.
“Prana is dedicated to progressing development of PBT2 as a treatment for this terrible disease that devastates lives and families.”
Orphan designation is granted by the EC to encourage the development of medicines to treat rare diseases. Rare diseases are defined as life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in Europe.